# An Exploratory Study of the Effects of a Single Dose of QAX576 (an Interleukin-13 Monoclonal Antibody) on Simulated Hayfever

> **NCT00584584** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 36 (actual)

## Conditions studied

- Allergic Rhinitis

## Interventions

- **DRUG:** QAX576
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00584584
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2008-08
- **Final completion:** —
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00584584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00584584, "An Exploratory Study of the Effects of a Single Dose of QAX576 (an Interleukin-13 Monoclonal Antibody) on Simulated Hayfever". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00584584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*